Phase 1/2a study of Lu-177-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
dc.contributor.author | Kolstad, A. | |
dc.contributor.author | Illidge, Timothy M | |
dc.contributor.author | Bolstad, N. | |
dc.contributor.author | Spetalen, S. | |
dc.contributor.author | Madsbu, U. | |
dc.contributor.author | Stokke, C. | |
dc.contributor.author | Blakkisrud, J. | |
dc.contributor.author | Londalen, A. | |
dc.contributor.author | O'Rourke, N. | |
dc.contributor.author | Beasley, M. | |
dc.contributor.author | Jurczak, W. | |
dc.contributor.author | Fagerli, U. M. | |
dc.contributor.author | Kascak, M. | |
dc.contributor.author | Bayne, M. | |
dc.contributor.author | Obr, A. | |
dc.contributor.author | Dahle, J. | |
dc.contributor.author | Rojkjaer, L. | |
dc.contributor.author | Pascal, V. | |
dc.contributor.author | Holte, H. | |
dc.date.accessioned | 2020-10-06T13:33:47Z | |
dc.date.available | 2020-10-06T13:33:47Z | |
dc.date.issued | 2020 | en |
dc.identifier.citation | Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, et al. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2020;4(17):4091-101. | en |
dc.identifier.pmid | 32877524 | en |
dc.identifier.doi | 10.1182/bloodadvances.2020002583 | en |
dc.identifier.uri | http://hdl.handle.net/10541/623335 | |
dc.description.abstract | For patients with indolent non-Hodgkin lymphoma who fail initial anti-CD20-based immunochemotherapy or develop relapsed or refractory disease, there remains a significant unmet clinical need for new therapeutic approaches to improve outcomes and quality of life. 177Lu-lilotomab satetraxetan is a next-generation single-dose CD37-directed radioimmunotherapy (RIT) which was investigated in a phase 1/2a study in 74 patients with relapsed/refractory indolent non-Hodgkin B-cell lymphoma, including 57 patients with follicular lymphoma (FL). To improve targeting of 177Lu-lilotomab satetraxetan to tumor tissue and decrease hematologic toxicity, its administration was preceded by the anti-CD20 monoclonal antibody rituximab and the "cold" anti-CD37 antibody lilotomab. The most common adverse events (AEs) were reversible grade 3/4 neutropenia (31.6%) and thrombocytopenia (26.3%) with neutrophil and platelet count nadirs 5 to 7 weeks after RIT. The most frequent nonhematologic AE was grade 1/2 nausea (15.8%). With a single administration, the overall response rate was 61% (65% in patients with FL), including 30% complete responses. For FL with ≥2 prior therapies (n = 37), the overall response rate was 70%, including 32% complete responses. For patients with rituximab-refractory FL ≥2 prior therapies (n = 21), the overall response rate was 67%, and the complete response rate was 24%. The overall median duration of response was 13.6 months (32.0 months for patients with a complete response). 177Lu-lilotomab satetraxetan may provide a valuable alternative treatment approach in relapsed/refractory non-Hodgkin lymphoma, particularly in patients with comorbidities unsuitable for more intensive approaches. This trial was registered at www.clinicaltrials.gov as #NCT01796171. | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1182/bloodadvances.2020002583 | en |
dc.title | Phase 1/2a study of Lu-177-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma | en |
dc.type | Article | en |
dc.contributor.department | Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway | en |
dc.identifier.journal | Blood Advances | en |
dc.description.note | en] | |
refterms.dateFOA | 2020-10-07T13:12:18Z |